$0.00
(Market cap
$23 Mln
Revenue (TTM)
$2 Mln
P/E Ratio
--
P/B Ratio
18.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-10.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1.4
-
Debt to Equity
-1.1
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
82,962,800
6 Years Aggregate
CFO
$-118.37 Mln
EBITDA
$-136.96 Mln
Net Profit
$-148.77 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Renalytix (RNLX)
| -63.9 | -13.4 | -51.1 | -65.8 | -79.5 | -- | -- |
|
BSE Sensex*
| -12.2 | -3.3 | -7.3 | -8.6 | 5.9 | 7.5 | 10.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
|---|---|---|---|
|
Renalytix (RNLX)
| -79.1 | -88.2 | -0.6 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Renalytix (RNLX)
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data... inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York. Read more
-
Chief Executive Officer
Mr. James R. McCullough M.B.A.
-
Chief Executive Officer
Mr. James R. McCullough M.B.A.
-
Headquarters
New York, NY
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Renalytix (RNLX)
What is the current share price of Renalytix plc (RNLX) Today?
The share price of Renalytix plc (RNLX) is $0.14 (NASDAQ) as of 06-Dec-2024 09:30 EDT. Renalytix plc (RNLX) has given a return of -79.5% in the last 3 years.
What is the current PB & PE ratio of Renalytix plc (RNLX)?
Since, TTM earnings of Renalytix plc (RNLX) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
What is the 52 Week High and Low of Renalytix plc (RNLX)?
The 52-week high and low of Renalytix plc (RNLX) are Rs -- and Rs -- as of 04-Jun-2026.
What is the market cap of Renalytix plc (RNLX)?
Renalytix plc (RNLX) has a market capitalisation of $ 23 Mln as on 06-Dec-2024. As per SEBI classification, it is a Small Cap company.
Should I invest in Renalytix plc (RNLX)?
Before investing in Renalytix plc (RNLX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.